U.S. FDA Approves Expanded Indication for AbbVie's MAVYRET® as First and Only Treatment for People with Acute Hepatitis C Virus Pharmaceutical Investing
Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer Pharmaceutical Investing
AbbVie Invites People Living with Migraine to Enter the Second Annual AbbVie Migraine Career Catalyst Award Contest to Support Their Professional Goals Pharmaceutical Investing
AbbVie to Present at the Goldman Sachs 46th Annual Global Healthcare Conference Pharmaceutical Investing
Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer Pharmaceutical Investing
Pfizer's BRAFTOVI® Combination Regimen Cuts the Risk of Death in Half for Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer Pharmaceutical Investing
